DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / Atlas Venture
Atlas Venture
Institutional venture firmBoston, MAatlasventure.comSEC venture capital fund adviserone firm, 2 filing advisers
This firm files as 2 advisers on atlasventure.com: Atlas Venture Life Science Advisors, LLC. Each keeps its own CRD, funds and filings; the grouping is the website each swore to on Form ADV and is recomputed every pass.
Thirty years at the leading-edge of medical innovation and we’re just getting started.
venture manager, reported GAV $2,399M across 7 vehicles
Importance
60
high
Active deployment
44
elevated
Emerging
0
low
Completeness
69
high
Freshness
100
high
Research priority
20
moderate
Identity and regulatory footprint
- Headquarters
- Boston, MAadviserinfo.sec.gov
- Office address
- 56 WAREHAM STREET, FLOOR 3, Boston, MA, 02118adviserinfo.sec.gov
- Business phone
- 617-588-2600adviserinfo.sec.gov
- Website
- http://www.atlasventure.com
- SEC adviser type
- exempt reporting adviseradviserinfo.sec.gov
- SEC exemption claimed
- venture capital fund adviseradviserinfo.sec.govItem 2.B(1): advises solely venture capital funds
- Latest Form ADV
- Mar 30, 2026
- Private funds reported
- 6 (6 venture capital funds)adviserinfo.sec.gov
- Private fund gross assets
- $2.0Badviserinfo.sec.govreported GAV of the funds, the adviser's own number; not fund size, not dry powder
- Owners on Schedule A
- Atlas Venture Advisors, LLC (General Partner), NA
- business email
- atlasventure@atlasventure.comatlasventure.compublished by the subject
- business phone
- 617-588-2600adviserinfo.sec.govpublished by the subject
Stated thesis versus observed behaviour
5 observed deals
Stated (the firm’s website)
- Sectors
- biotech
- Stages
- not stated or not yet read
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation
series b 100%
Stage at first entry
series b 100%
Sectors
unknown 100%
lead rate 50%follow-on rate 0%new logos, 12 months 5
Funds and vehicles
7 reported, 6 no longer reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| Atlas Venture Fund XIV, L.P. | Fund | 2024 form d first sale | Newly closed | unknown | unknown | $450M of $450M | Dec 5, 2024 |
| Atlas Venture Fund Ix, L.P. | Fund | 2013 adv first reported | Harvest | $432M Mar 26, 2024 | 32 | unknown | unknown |
| Atlas Venture Fund Viii, L.P. | Fund | unknown | Unknown | $1.3B Mar 26, 2024 | 39 | unknown | unknown |
| Atlas Venture Fund VI, L.P. | Fund | unknown | Unknown | $596M Mar 26, 2024 | 51 | unknown | unknown |
| Atlas Venture Fund VII, L.P. | Fund | unknown | Unknown | $33.1M Mar 26, 2024 | 49 | unknown | unknown |
| Atlas Venture Entrepreneurs Fund VI, L.P. | Fund | unknown | Unknown | $18.3M Mar 26, 2024 | 26 | unknown | unknown |
| Atlas Venture Fund VI Gmbh and Co. Kg | Fund | unknown | Unknown | $11.0M Mar 26, 2024 | 4 | unknown | unknown |
| Atlas Venture Fund V, L.P. | Fund | unknown | Wound down | $13.4M Mar 30, 2015 | 60 | unknown | unknown |
| Atlas Venture Fund III, L.P. | Fund | unknown | Wound down | $12.2M May 21, 2012 | 30 | unknown | unknown |
| Atlas Venture Fund IV, L.P. | Fund | unknown | Wound down | $1.5M Mar 28, 2013 | 40 | unknown | unknown |
| Atlas Venture Entrepreneurs Fund III, L.P. | Fund | unknown | Wound down | $574,981 May 21, 2012 | 60 | unknown | unknown |
| Atlas Venture Entrepreneurs Fund V, L.P. | Fund | unknown | Wound down | $546,374 Mar 30, 2015 | 82 | unknown | unknown |
| Atlas Venture Entrepreneurs Fund IV, L.P. | Fund | unknown | Wound down | $416,414 Mar 28, 2013 | 60 | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
92 current, 10 departed
All Categories
AssociateInvestment Team
Douglas Kerr
Board or advisoryAtlas Advisor; Chief Medical Officer, Dyne Therapeutics
Jared Cumming
Board or advisoryAtlas Advisor; Chief Scientific Officer, Matchpoint Therapeutics
Robert Hughes
Board or advisoryAtlas Advisor; EVP Drug Discovery & Preclinical Development, Rectify Pharmaceuticals
Rubina Parmar
Board or advisoryAtlas Advisor; Head of Technology, Stealth NewCo
Vito Palombella
Board or advisoryAtlas Advisor; Chief Scientific Officer, TRIANA Biomedicines
Alex Harding
Founder or executiveEntrepreneur-in-Residence; Chief Executive Officer, Stealth NewCo
Alex Lugovskoy
Founder or executiveAtlas Advisor; Chief Executive Officer, Diagonal Therapeutics
Andre Turenne
Founder or executiveAtlas Advisor; Chief Executive Officer, Matchpoint Therapeutics
Bernard Ravina
Founder or executiveAtlas Advisor; Founder and Chief Executive Officer, Vima Therapeutics
Constantine Chinoporos
Founder or executiveAtlas Advisor; Executive Chairman, Rectify Pharmaceuticals
Dania Rabah
Founder or executiveEntrepreneur-in-Residence; Co-Founder and Chief Scientific Officer, Stealth NewCo
Diana Brainard
Founder or executiveEntrepreneur-in-Residence; Chief Executive Officer, Stealth NewCo
Don Nicholson
Founder or executiveAtlas Advisor; Executive Chairman, Disc Therapeutics; Former Chief Executive Officer, Nimbus Therapeutics
Eben Tessari
Founder or executiveEntrepreneur-in-Residence; Chief Executive Officer, Calixis
Geoff McDonough
Founder or executiveAtlas Advisor; Former Chief Executive Officer, Generation Bio
Geraldine (Gerry) Harriman
Founder or executiveAtlas Advisor; Co-Founder and Chief Scientific Officer, HotSpot Therapeutics
Jodie Morrison
Founder or executiveAtlas Advisor; Chief Executive Officer, Q32 Bio
John Cox
Founder or executiveAtlas Advisor; President and Chief Executive Officer, Dyne Therapeutics
John Quisel
Founder or executiveAtlas Advisor; President & Chief Executive Officer, Disc Medicine
Jonathan Montagu
Founder or executiveAtlas Advisor; Chief Executive Officer, HotSpot Therapeutics
Judith Dunn
Founder or executiveAtlas Advisor; President and Head of R&D, Vima Therapeutics
Natalia Misciattelli
Founder or executiveAtlas Advisor; Chief Executive Officer, AAVantgarde Bio
Nello Mainolfi
Founder or executiveAtlas Advisor; Chief Executive Officer and President, Kymera Therapeutics
Nick Keen
Founder or executiveEntrepreneur-in-Residence; Founder & Chief Scientific Officer, Stealth NewCo
Niranjan Kameswaran
Founder or executiveAtlas Advisor; Chief Executive Officer, Ethyreal Bio
Owen Hughes
Founder or executiveEntrepreneur-in-Residence; Chief Executive Officer, Stealth NewCo
Pascal Fortin
Founder or executiveEntrepreneur-in-Residence; President and Chief Scientific Officer, Stealth NewCo
Peter Smith
Founder or executiveAtlas Advisor; Co-founder, President, Chief Executive Officer, Remix Therapeutics
Ram Aiyar
Founder or executiveAtlas Advisor, Chief Executive Officer & President, Korro Bio
Samantha Singer
Founder or executiveEntrepreneur in Residence; Chief Executive Officer and President, Stealth NewCo
Shelia Violette
Founder or executiveAtlas Advisor; Founder, Chief Scientific Officer, President of Research, Q32 Bio
Steven Sweeney
Founder or executiveEntrepreneur-in-Residence; Chief Executive Officer, Stealth NewCo
Vishal Patel
Founder or executiveAtlas Advisor; Chief Executive Officer, Triveni Bio
Kristen Margeson
Investor relationsVice President of Investor Relations and Marketing
Timothy P. Reilly
OtherEntrepreneur-in-Residence; Head of R&D, Stealth NewCo
David Grayzel
PartnerPartner
Jason Rhodes
PartnerPartner
Kevin Bitterman
PartnerPartner
Michael Gladstone
PartnerPartner
Peter Barrett
PartnerPartner Legacy Funds
Alfica Sehgal
Platform and operationsEntrepreneur-in-Residence; Chief Scientific Officer, Judo Bio
Angela Lam
Platform and operationsExecutive Assistant
Diana Francis
Platform and operationsController
Eleanor Ronan
Platform and operationsManager of Talent and HR Operations
Elena Ridloff
Platform and operationsAtlas Advisor; Chief Financial Officer & Head of Corporate Development, Sionna Therapeutics
Eric Schmid
Platform and operationsVice President, Legal Affairs
Farah Lewis
Platform and operationsExecutive Assistant
Francis Victor Castellucci
Platform and operationsGeneral Counsel, Secretary · since Apr 1, 2008
Francis Victor Castellucci
Platform and operationsGeneral Counsel, Secretary · since Apr 1, 2008
Haojing Rong
Platform and operationsEntrepreneur-in-Residence; Chief Development Officer, Spolia Therapeutics
Jeff Trigilio
Platform and operationsEntrepreneur-in-Residence; Chief Financial and Chief Business Officer, Stealth NewCo
Josh Powers
Platform and operationsFinance Manager
Katharine Unangst
Platform and operationsExecutive Assistant
Kyle Shuckerow
Platform and operationsFinance Manager
Lainey Rabinow
Platform and operationsExecutive Assistant
Laura Alessio
Platform and operationsDirector of Portfolio Operations
Mark Tebbe
Platform and operationsEntrepreneur-in-Residence; Chief Technology Officer, Spolia Therapeutics
Meaghan Gallagher
Platform and operationsExecutive Assistant
Mike Forkel
Platform and operationsVice President, Finance
Ommer Chohan
Platform and operationsChief Financial Officer
Sarah Gerrish
Platform and operationsExecutive Assistant
Scott Ribich
Platform and operationsEntrepreneur-in-Residence; Chief Scientific Officer, Stealth NewCo
Sean Burns
Platform and operationsEntrepreneur-in-Residence; Chief Scientific Officer, Stealth NewCo
Travis Leigh Macinnes
Platform and operationsChief Financial Officer And Treasurer · since Sep 1, 2017
Travis Leigh Macinnes
Platform and operationsChief Financial Officer And Treasurer · since Sep 1, 2017
Aimee Raleigh
PrincipalPrincipal
Bruce Lee Booth
PrincipalShareholder, Director, Vice President · since Dec 1, 2011
Bruce Lee Booth
PrincipalShareholder, Director, Vice President · since Dec 1, 2011
George Vlasuk
PrincipalAtlas Advisor; Board Director, Nimbus Therapeutics
Jean-Francois Bernard Formela
PrincipalShareholder, Director, Vice President · since Feb 1, 1999
Jean-Francois Bernard Formela
PrincipalShareholder, Director, Vice President · since Feb 1, 1999
Jeffrey Lyle Fagnan
PrincipalShareholder, Director, Vice President · since Apr 1, 2008
Jeffrey Lyle Fagnan
PrincipalShareholder, Director, Vice President · since Apr 1, 2008
Jernej Godec
PrincipalPrincipal
Mark Iwicki
PrincipalAtlas Advisor; Board Director, Nimbus, Q32
Maurizio Fazio
PrincipalPrincipal
Peter Barrett
PrincipalShareholder, Director, Vice President · since Apr 1, 2008
Peter Barrett
PrincipalShareholder, Director, Vice President · since Apr 1, 2008
Akshay Vaishnaw
Venture partnerVenture Partner
Bob Copeland
Venture partnerVenture Partner
Charlie Albright
Venture partnerVenture Partner
Jeff Albers
Venture partnerVenture Partner
John Maraganore
Venture partnerVenture Advisor
Linda C. Bain
Venture partnerVenture Partner
Phillip Samayoa
Venture partnerVenture Partner; Chief Operating Officer, Ethyreal Bio
Praveen Tipirneni
Venture partnerVenture Partner; Chief Executive Officer, Caldera Therapeutics
Rajesh Devraj
Venture partnerVenture Partner; President & Chief Executive Officer, Rectify Pharmaceuticals
Steven Robinette
Venture partnerVenture Partner; Chief Executive Officer, Spolia Therapeutics
Julia Pian
Vice presidentSenior Associate
Justin Feng
Vice presidentSenior Associate
Stella Paffenholz
Vice presidentSenior Associate
10 departed (kept with end dates)
- Dania Rabah · Entrepreneur-in-Residence; Co-Founder and Chief Scientific Officer, Stealth NewCo · ? to Sep 16, 2026 Inference
- John Quisel · Atlas Advisor; President & Chief Executive Officer, Disc Medicine · ? to Sep 16, 2026 Inference
- Caroline Breitbach · Partner · ? to Sep 16, 2026 Inference
- Eric Schmid · Vice President, Legal Affairs · ? to Sep 16, 2026 Inference
- Gretchen Marie Mccarey · Chief Financial Officer, Treasurer · Sep 1, 2014 to Mar 30, 2016 Inference
- Kristen Lee Laguerre · Chief Financial Officer, Vice President, Treasurer And Secretary · Apr 1, 2008 to Oct 28, 2014 Inference
- Christopher Paul Lynch · Shareholder, Director, Vice President · Nov 1, 2012 to Mar 30, 2017 Inference
- Frederic Geoffrey Destin · Shareholder, Director, Vice President · Dec 1, 2011 to Oct 28, 2014 Inference
- Ryan Robert Moore · Shareholder, Director, Vice President · Dec 1, 2011 to Mar 26, 2024 Inference
- Jeff Albers · Venture Partner · ? to Sep 16, 2026 Inference
Investments on record
5 edges, 5 companies, 0 partner-attributed
| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| LifeSciVC | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Show + Tell | portfolio listing | unknown | unknown | unknown | unknown | Sep 16, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Aavantgardebio | portfolio listing | unknown | unknown | unknown | unknown | Sep 14, 2026 | Fact Venture organization websites (about, team, portfolio, thesis, news pages) |
| Pivot Energy | Funding round | lead | unknown | $225M | unknown | Dec 17, 2025 | Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) |
| Kailera Therapeutics | Series B · Series B | participant | unknown | $600M | unknown | Oct 14, 2025 | Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) |
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
15 relationships from shared deals, counted for the whole firm
Omega Fund Management, LLC 1 shared · one timeHealthQuest Capital 1 shared · one timeEnergy Capital Partners 1 shared · one time · we led 1First Citizens 1 shared · one time · they led 1 · we led 1Perseverance Capital 1 shared · one timeInvus 1 shared · one timeKailera 1 shared · one timeSurveyor Capital 1 shared · one timeRoyalty Pharma 1 shared · one timeBain Capital Private Equity 1 shared · one timeAdage Capital Management 1 shared · one timeBain Capital Life Sciences 1 shared · one timeCanada Pension Plan Investment Board 1 shared · one timeQatar Investment Authority 1 shared · one timeRTW Investments 1 shared · one time
Limited partners
0 disclosed
No LP commitment on record. An LP edge needs a public disclosure with a quote: a pension report (see Limited partners for the plans read), a fund announcement naming the LP, or a Form ADV owner. The fund page carries the LP’s reported performance.
Timeline
33 dated events
- Sep 16, 2026Aavantgardebio no longer listed on Atlas Venture's portfolio pageRemoved from portfolio pagePortfolioInferenceAavantgardebioVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Dania Rabah (Entrepreneur-in-Residence; Co-Founder and Chief Scientific Officer, Stealth NewCo) no longer on the team page of Atlas VenturePerson leftPeopleInferenceDania RabahVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Caroline Breitbach (Partner) no longer on the team page of Atlas VenturePerson leftPeopleInferenceCaroline BreitbachVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Jeff Albers (Venture Partner) no longer on the team page of Atlas VenturePerson leftPeopleInferenceJeff AlbersVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026Eric Schmid (Vice President, Legal Affairs) no longer on the team page of Atlas VenturePerson leftPeopleInferenceEric SchmidVenture organization websites (about, team, portfolio, thesis, news pages)
- Sep 16, 2026John Quisel (Atlas Advisor; President & Chief Executive Officer, Disc Medicine) no longer on the team page of Atlas VenturePerson leftPeopleInferenceJohn QuiselVenture organization websites (about, team, portfolio, thesis, news pages)
- Mar 26, 2024Ryan Robert Moore (Shareholder, Director, Vice President) no longer on Schedule A of Atlas Venture
- Sep 1, 2017Travis Leigh Macinnes joined Schedule A of Atlas Venture as Chief Financial Officer And Treasurer
- Mar 30, 2017Christopher Paul Lynch (Shareholder, Director, Vice President) no longer on Schedule A of Atlas Venture
- Mar 30, 2016Atlas Venture Fund V, L.P. no longer reported on Form ADV by Atlas VentureFund no longer reportedFundsInferenceAtlas Venture Fund V, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 30, 2016Gretchen Marie Mccarey (Chief Financial Officer, Treasurer) no longer on Schedule A of Atlas Venture
- Mar 30, 2016Atlas Venture Entrepreneurs Fund V, L.P. no longer reported on Form ADV by Atlas VentureFund no longer reportedFundsInferenceAtlas Venture Entrepreneurs Fund V, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Oct 28, 2014Kristen Lee Laguerre (Chief Financial Officer, Vice President, Treasurer And Secretary) no longer on Schedule A of Atlas Venture
- Oct 28, 2014Frederic Geoffrey Destin (Shareholder, Director, Vice President) no longer on Schedule A of Atlas Venture
- Sep 1, 2014Gretchen Marie Mccarey joined Schedule A of Atlas Venture as Chief Financial Officer, Treasurer
- Mar 27, 2014Atlas Venture Fund IV, L.P. no longer reported on Form ADV by Atlas VentureFund no longer reportedFundsInferenceAtlas Venture Fund IV, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 27, 2014Atlas Venture Entrepreneurs Fund IV, L.P. no longer reported on Form ADV by Atlas VentureFund no longer reportedFundsInferenceAtlas Venture Entrepreneurs Fund IV, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2013Atlas Venture Fund III, L.P. no longer reported on Form ADV by Atlas VentureFund no longer reportedFundsInferenceAtlas Venture Fund III, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2013Atlas Venture Fund Ix, L.P. first reported on Form ADV by Atlas Venture (Venture Capital Fund), GAV $208,500,000Fund first reported on Form ADVFundsFactAtlas Venture Fund Ix, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 28, 2013Atlas Venture Entrepreneurs Fund III, L.P. no longer reported on Form ADV by Atlas VentureFund no longer reportedFundsInferenceAtlas Venture Entrepreneurs Fund III, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Nov 1, 2012Christopher Paul Lynch joined Schedule A of Atlas Venture as Shareholder, Director, Vice President
- Mar 29, 2012Atlas Venture Fund IV, L.P. first reported on Form ADV by Atlas Venture (Venture Capital Fund), GAV $35,096,699Fund first reported on Form ADVFundsFactAtlas Venture Fund IV, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2012Atlas Venture Fund VII, L.P. first reported on Form ADV by Atlas Venture (Venture Capital Fund), GAV $417,692,646Fund first reported on Form ADVFundsFactAtlas Venture Fund VII, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2012Atlas Venture Fund Viii, L.P. first reported on Form ADV by Atlas Venture (Venture Capital Fund), GAV $286,435,245Fund first reported on Form ADVFundsFactAtlas Venture Fund Viii, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2012Atlas Venture Entrepreneurs Fund V, L.P. first reported on Form ADV by Atlas Venture (Venture Capital Fund), GAV $1,903,752Fund first reported on Form ADVFundsFactAtlas Venture Entrepreneurs Fund V, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2012Atlas Venture first filed Form ADV (ERA, venture capital fund adviser exemption)First SEC adviser filingOrganizationFactSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2012Atlas Venture Entrepreneurs Fund IV, L.P. first reported on Form ADV by Atlas Venture (Venture Capital Fund), GAV $425,759Fund first reported on Form ADVFundsFactAtlas Venture Entrepreneurs Fund IV, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2012Atlas Venture Entrepreneurs Fund III, L.P. first reported on Form ADV by Atlas Venture (Venture Capital Fund), GAV $574,981Fund first reported on Form ADVFundsFactAtlas Venture Entrepreneurs Fund III, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2012Atlas Venture Fund VI, L.P. first reported on Form ADV by Atlas Venture (Venture Capital Fund), GAV $184,375,361Fund first reported on Form ADVFundsFactAtlas Venture Fund VI, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2012Atlas Venture Fund V, L.P. first reported on Form ADV by Atlas Venture (Venture Capital Fund), GAV $66,811,561Fund first reported on Form ADVFundsFactAtlas Venture Fund V, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2012Atlas Venture Fund VI Gmbh and Co. Kg first reported on Form ADV by Atlas Venture (Venture Capital Fund), GAV $3,630,091Fund first reported on Form ADVFundsFactAtlas Venture Fund VI Gmbh and Co. KgSEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2012Atlas Venture Fund III, L.P. first reported on Form ADV by Atlas Venture (Venture Capital Fund), GAV $12,187,613Fund first reported on Form ADVFundsFactAtlas Venture Fund III, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
- Mar 29, 2012Atlas Venture Entrepreneurs Fund VI, L.P. first reported on Form ADV by Atlas Venture (Venture Capital Fund), GAV $5,706,753Fund first reported on Form ADVFundsFactAtlas Venture Entrepreneurs Fund VI, L.P.SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
Classification history
- Sep 15, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $2,399M across 7 vehicles
- Sep 12, 2026Institutional venture firm (confirmed, 95%, cls-1)venture manager, reported GAV $1,774M across 4 vehicles
Evidence
56 observations from 4 sources